Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 8/20 | 0.52 |
| ▸ | PKLR | P30613 | 3/20 | 0.52 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.34 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31618133 | 0.84 | PKM (0.44) | PKMPKLRCES2CES1IKBKB | |
| SCHEMBL2021516 | 0.77 | PKM (0.44) | PKMPKLRCES2CES1IKBKB | |
| SCHEMBL4139118 | 0.76 | PKM (0.50) | PKMPKLRCES2CES1IKBKB | |
| SCHEMBL29141548 | 0.76 | CA1 (0.41) | PKMPKLRCES2CES1BCHE | |
| SCHEMBL677588 | 0.76 | CA1 (0.52) | PKMPKLRPTGES2 | |
| SCHEMBL532887 | 0.76 | PKM (0.50) | PKMPKLRCES2CES1IKBKB | |
| SCHEMBL795356 | 0.76 | PKM (0.50) | PKMPKLRCES2CES1IKBKB | |
| SCHEMBL6038889 | 0.76 | PKM (0.50) | PKMPKLRCES2CES1IKBKB | |
| SCHEMBL3926685 | 0.74 | PKM (0.48) | PKMPKLRCES2CES1IKBKB | |
| SCHEMBL3926679 | 0.74 | PKM (0.48) | PKMPKLRCES2CES1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117279889-B | Substituted fluorosulfates and uses thereof | 深圳湾实验室 | 2025-04-25 | — | — | CN | disclosed |
| CN-117279889-A | Substituted fluorosulfates and uses thereof | 深圳湾实验室 | 2023-12-22 | — | — | CN | disclosed |
| US-7718702-B2 | Sulfonamide-containing benzene derivatives; cancer and inflammatory, immunomodulatory or respiratory diseases | SCHERING CORPORATION (US) | 2010-05-18 | — | — | US | disclosed |
| US-7507767-B2 | Cannabinoid receptor ligands | SCHERING CORPORATION (US) | 2009-03-24 | — | — | US | disclosed |
| US-7067539-B2 | Cannabinoid receptor ligands | SCHERING CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060009528-A1 | Cannabinoid receptor ligands | SCHERING CORPORATION | 2006-01-12 | — | — | US | disclosed |
| EP-1539662-A1 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014825-A1 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030232859-A1 | Cannabinoid receptor ligands | SCHERING CORPORATION | 2003-12-18 | — | — | US | disclosed |
| EP-1368308-A1 | CANNABINOID RECEPTOR LIGANDS | Schering Corporation (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002062750-A9 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORP (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030096844-A1 | Sulfonamide-containing benzene derivatives which exhibit anti-inflammatory and immunodulatory activity | SCHERING CORPORATION | 2003-05-22 | — | — | US | disclosed |
| WO-2002062750-A1 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
| US-4369145-A | Preparation of fluorobenzenesulfonyl fluorides by exchange fluorination | RHONE-POULENC INDUSTRIES (FR) | 1983-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009528-A1 | Cannabinoid receptor ligands | CNR1, CNR2, GPR18 | PKM 4291/4885PKLR 2687/4885CES2 741/4885 |
| US-20030096844-A1 | Sulfonamide-containing benzene derivatives which exhibit anti-inflammatory and immunodulatory activity | SULT2A1, NFKBIA, SULT1A1 | PKM 4210/4885PKLR 2825/4885CES2 912/4885 |
| US-20030232859-A1 | Cannabinoid receptor ligands | CNR1, CNR2, GPR18 | PKM 4463/4885PKLR 3154/4885CES2 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.